日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial data.

MK-6194（一种旨在选择性激活调节性 T 细胞的 IL-2 突变体）的安全性、药代动力学和药效学：单次递增剂量和多次递增剂量试验数据

期刊:Immunohorizons
影响因子:
doi:10.1093/immhor/vlaf005
Scheid Johannes F, Cunningham-Bussel Kiki, Kim Nancy, Agarwal Shiuli, Nieddu Garrett, Cote Josee, Lemoine Lieselotte, Decaesteker Tatjana, Mendez Luis, Paul Erina, Love-Gregory Latisha, Contreras Alejandra Virginia, Zhao Xuemei, Franco-Dilone Lucia, Pang Ling, Baltus Gretchen A, Beaumont Maribel, Shah Ketal, Higginson-Scott Nathan, Kis-Toth Katalin, Otipoby Kevin L, Viney Joanne L, Sicard Eric, Rottey Sylvie, Sundy John S, Van Dyck Kristien, Laethem Tine, Larson Patrick, Sutradhar Santosh, Wnek Richard, Bueters Tjerk, Lai Eseng, Stoch S Aubrey, Iwamoto Marian, Robbins Jonathan A
细胞生物学
发表日期：2025
文献求助 收藏

Phase 1 Study of MK-5475, an Inhaled Soluble Guanylate Cyclase Stimulator, in Participants with Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease

一项针对慢性阻塞性肺疾病相关肺动脉高压患者的吸入性可溶性鸟苷酸环化酶刺激剂MK-5475的I期研究

期刊:International Journal of Chronic Obstructive Pulmonary Disease
影响因子:3.1
doi:10.2147/COPD.S454905
Bajwa, Ednan K; Cislak, Dawn; Kumar, Amit; Li, Dan; Messina, Eric J; Reynders, Tom; Denef, Jean-François; Corcea, Vasile; Buch, Ketan P; Lai, Eseng; Stoch, S Aubrey
肺动脉高压
心血管
慢性阻塞性肺疾病
发表日期：2024
文献求助 收藏

A randomized phase 1 study of safety, tolerability, and pharmacokinetics of MK-1088, a novel dual adenosine receptor antagonist, in healthy adult participants

一项针对健康成年受试者的随机 I 期研究，旨在评估新型双重腺苷受体拮抗剂 MK-1088 的安全性、耐受性和药代动力学。

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-024-01462-y
Gupta, Pranav; Chatterjee, Manash; Kim, Yeonil; Deschamps, Kathleen; Lemoine, Lieselotte; Van Dyck, Kristien; Matthews, Catherine Zhou; Rottey, Sylvie; Stoch, Aubrey; Lai, Eseng
信号转导
发表日期：2024
文献求助 收藏

Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial

基于麻疹载体的SARS-CoV-2候选疫苗V591在成人中的安全性和免疫原性：一项1/2期随机、双盲、安慰剂对照、剂量范围试验的结果

期刊:EBioMedicine
影响因子:10.8
doi:10.1016/j.ebiom.2021.103811
Vanhoutte, Frédéric; Liu, Wen; Wiedmann, Richard T; Haspeslagh, Liesbeth; Cao, Xin; Boundy, Keith; Aliprantis, Antonios; Davila, Michelle; Hartzel, Jonathan; Li, Jianing; McGuire, Mac; Ramsauer, Katrin; Tomberger, Yvonne; Tschismarov, Roland; Brown, Deborah D; Xu, Weifeng; Sachs, Jeffrey R; Russell, Kevin; Stoch, S Aubrey; Lai, Eseng
SARS-CoV-2
麻疹
免疫/内分泌
发表日期：2022
文献求助 收藏

Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis

预测中和呼吸道合胞病毒（RSV）抗体预防效果的正向和反向转化方法

期刊:EBioMedicine
影响因子:10.8
doi:10.1016/j.ebiom.2021.103651
Maas, Brian M; Lommerse, Jos; Plock, Nele; Railkar, Radha A; Cheung, S Y Amy; Caro, Luzelena; Chen, Jingxian; Liu, Wen; Zhang, Ying; Huang, Qinlei; Gao, Wei; Qin, Li; Meng, Jie; Witjes, Han; Schindler, Emilie; Guiastrennec, Benjamin; Bellanti, Francesco; Spellman, Daniel S; Roadcap, Brad; Kalinova, Mariya; Fok-Seang, Juin; Catchpole, Andrew P; Espeseth, Amy S; Stoch, S Aubrey; Lai, Eseng; Vora, Kalpit A; Aliprantis, Antonios O; Sachs, Jeffrey R
微生物学
发表日期：2021
文献求助 收藏

A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults

一项 1 期随机、安慰剂对照研究，旨在评估基于 mRNA 的 RSV 融合前 F 蛋白疫苗在健康青年和老年人群中的安全性和免疫原性。

期刊:Human Vaccines & Immunotherapeutics
影响因子:3.5
doi:10.1080/21645515.2020.1829899
Aliprantis, Antonios O; Shaw, Christine A; Griffin, Paul; Farinola, Nicholas; Railkar, Radha A; Cao, Xin; Liu, Wen; Sachs, Jeffrey R; Swenson, Christine J; Lee, Heather; Cox, Kara S; Spellman, Daniel S; Winstead, Colleen J; Smolenov, Igor; Lai, Eseng; Zaks, Tal; Espeseth, Amy S; Panther, Lori
免疫/内分泌
发表日期：2021
文献求助 收藏

Pharmacokinetic-pharmacodynamic (dipeptidyl peptidase-4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once-weekly administered omarigliptin

建立药代动力学-药效学（二肽基肽酶-4抑制）模型，以支持糖尿病患者（包括肾功能不全患者）每周一次给药的奥马格列汀的剂量合理性。

期刊:British Journal of Clinical Pharmacology
影响因子:3
doi:10.1111/bcp.14103
Jain, Lokesh; Chain, Anne S Y; Tatosian, Daniel A; Hing, Jeremy; Passarell, Julie A; Kauh, Eunkyung A; Lai, Eseng
糖尿病
代谢
发表日期：2019
文献求助 收藏

A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus

一项随机、安慰剂对照研究，旨在评估每周一次的 DPP-4 抑制剂奥马格列汀在 2 型糖尿病患者中的心血管安全性

期刊:Cardiovascular Diabetology
影响因子:10.6
doi:10.1186/s12933-017-0593-8
Gantz, Ira; Chen, Menghui; Suryawanshi, Shailaja; Ntabadde, Catherine; Shah, Sukrut; O'Neill, Edward A; Engel, Samuel S; Kaufman, Keith D; Lai, Eseng
糖尿病
代谢
发表日期：2017
文献求助 收藏

Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy

一项随机临床试验比较了每周一次的二肽基肽酶-4 (DPP-4) 抑制剂奥马格列汀与每日一次的 DPP-4 抑制剂西格列汀在二甲双胍单药治疗控制不佳的 2 型糖尿病患者中的疗效和安全性。

期刊:Diabetes Obesity & Metabolism
影响因子:5.7
doi:10.1111/dom.12832
Goldenberg, Ronald; Gantz, Ira; Andryuk, Paula J; O'Neill, Edward A; Kaufman, Keith D; Lai, Eseng; Wang, Yin Na; Suryawanshi, Shailaja; Engel, Samuel S
糖尿病
代谢
发表日期：2017
文献求助 收藏

A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes

一项随机、安慰剂和西格列汀对照试验，旨在评估每周一次的二肽基肽酶-4抑制剂奥马格列汀在日本2型糖尿病患者中的安全性和有效性。

期刊:Diabetes Obesity & Metabolism
影响因子:5.7
doi:10.1111/dom.12988
Gantz, Ira; Okamoto, Taro; Ito, Yuka; Okuyama, Kotoba; O'Neill, Edward A; Kaufman, Keith D; Engel, Samuel S; Lai, Eseng
糖尿病
代谢
发表日期：2017
文献求助 收藏